Healthcare Worker Exposure Response & Outcomes of Hydroxychloroquine Trial (HERO-HCQ)
HERO-HCQ is a randomized clinical trial of approximately 2,000 HERO Registry participants testing if hydroxychloroquine (HCQ, brand name Plaquenil®) can prevent COVID-19 infection in healthcare workers.
We would like to thank all HERO Registry members who participated in HERO-HCQ. and played a critical role in generating the study results. We appreciate your time and commitment to help find solutions to protect healthcare workers, their families, and communities during the COVID-19 pandemic.
Read the results in this pre-print publication or designed summary of results.
Why hydroxychloroquine?
Hydroxychloroquine is approved by the U.S. Food and Drug Administration to treat malaria and certain conditions such as rheumatoid arthritis and lupus. In HERO-HCQ, we will test its use to prevent COVID-19 infection.
Summary of Results
Acknowledgements
The HERO research program is made possible by contributions and services from other organizations, including:
- Almac Group, for drug distribution and randomization services
- Covance, for central lab coordination and testing
- Sandoz, the Novartis generics and biosimilars division, for the donated study medication and matching placebo
- Verily Life Sciences, for software and technology to support the participant portal and secure data platform